Health News Archive - April 25, 2009
15% of botox patients are now over 60 - Plastic Surgery increased too, with breast implants and facelifts increasing by a third - Longer lives, bigger bank balances and stunning senior celebs are influencing factors. MANCHESTER, England, April 25 /PRNewswire/ -- A NEW trend in beauty has been seen by staff at Transform, the UK's leading plastic surgeons and non-surgical treatments: the rise of Botox Grannies. More and more women over 60 are having non-surgical treatments including Botox, dermal fillers and skin peels and treatments, as well as plastic surgery such as breast implants and facelifts. Encouraged by their daughters and the increasing high profiles and media coverage of amazing looking celebrities who are in their 50s, 60s and 70s, such as Joan Collins, Jane Seymour and Lulu, UK's Botox Grannies are driving a new demand for non-surgical cosmetic treatments. Plastic Surgery and Botox Grannies Transform Plastic Surgery, the UK's leading cosmetic surgeons and non-surgical
NORTH HAVEN and MIDDLETOWN, Conn., April 25 /PRNewswire/ -- Anthem Blue Cross and Blue Shield and Middlesex Hospital in Middletown announced today they have reached agreement on the continuation of their network arrangement.
Recent medical studies have shown a significant rise in the number of women who choose to have both breasts surgically removed after being diagnosed with cancer in only one breast.
In ground-breaking new research conducted on mice, scientists have observed that the antibodies produced by pregnant mothers are transmitted to the fetus and may cause inflammation in the childâ€™s brain.
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered how to turn off a certain receptor that promotes the growth of leukemia cells.
A new study challenges long-standing expectations that men are promiscuous and women tend to be more particular when it comes to choosing a mate.
Every brain has a soundtrack. Its tempo and tone will vary, depending on mood, frame of mind, and other features of the brain itself.
- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and/or severe adverse events across the two Phase 3 trials, versus peginterferon alfa-2a - - Submission of global marketing applications planned in fall 2009 - ROCKVILLE, Md., April 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
Dartmouth Medical School researchers have devised a novel approach for thwarting the relentless bacterial infections that thrive in the lungs of people with cystic fibrosis (CF), unlocking new possibilities against a tenacious and toxic hallmark of the common genetic disease.
Reduces tumor growth by 75 percent by disrupting blood vessel formation.